0 21

Cited 0 times in

Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study

Authors
 Sun Jae Lee  ;  Hyung Joon Yim  ;  Seong Gyu Hwang  ;  Yeon Seok Seo  ;  Ji Hoon Kim  ;  Eileen L Yoon  ;  Joong Min Lee  ;  Bo Hyun Kim  ;  Sang Jong Park  ;  Young Min Park  ;  Hong Soo Kim  ;  Se Hwan Lee  ;  Sang Hoon Ahn  ;  Jeong Il Lee  ;  Jin Woo Lee  ;  In Hee Kim  ;  Hyung Soo Kim  ;  Sun Pyo Hong 
Citation
 SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, Vol.48 : 196-204, 2013-02 
Journal Title
 SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 
ISSN
 0036-5521 
Issue Date
2013-02
MeSH
Adenine / analogs & derivatives* ; Adenine / therapeutic use ; Adult ; Antiviral Agents / therapeutic use* ; Drug Administration Schedule ; Drug Resistance, Viral* ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Guanine / analogs & derivatives* ; Guanine / therapeutic use ; Hepatitis B, Chronic / drug therapy* ; Hepatitis B, Chronic / virology ; Humans ; Kaplan-Meier Estimate ; Lamivudine / therapeutic use* ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; Organophosphonates / therapeutic use* ; Retrospective Studies ; Treatment Outcome ; Viral Load
Abstract
Objectives: To compare the efficacy of rescue therapies in lamivudine (LAM)-resistant chronic hepatitis B (CHB) infections including: (1) adefovir dipivoxil (ADV) monotherapy, (2) ADV plus LAM combination therapy and (3) entecavir (ETV) 1.0 mg monotherapy. Materials and methods: The authors designed a multicenter-retrospective study. Eight institutions participated in the study from Korea. Results: A total of 343 LAM-resistant CHB patients were enrolled. The proportion of patients with undetectable serum hepatitis B virus (HBV) DNA levels at month 24 after the initiation of rescue therapy was higher in the ADV plus LAM combination therapy group (39/64, 60.9%) than in the ADV monotherapy (50/126, 39.7%) and ETV 1.0 mg monotherapy (19/48, 39.6%) groups (p = 0.014). Mean serum HBV DNA levels at 24 months were 2.07 ± 1.21 log(10) IU/ml in the ADV plus LAM combination therapy group, 2.74 ± 1.74 log(10) IU/ml in the ADV monotherapy group and 3.08 ± 1.97 log(10) IU/ml in the ETV 1.0 mg monotherapy group (p = 0.014). In multivariate analysis, a finding of undetectable serum HBV DNA level at 6 months and ADV plus LAM combination therapy (vs. ADV) was an independent factor for predicting undetectable serum HBV DNA at month 24 (odds ratio, 1.003; 95% confidence interval, 1.000-1.006; p = 0.026). Conclusions: ADV plus LAM combination therapy is more effective in reducing viral load than switching to ADV or ETV 1.0 mg in patients with LAM-resistant CHB.
Full Text
https://www.tandfonline.com/doi/full/10.3109/00365521.2012.722671
DOI
10.3109/00365521.2012.722671
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/178518
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links